Pharma Pulse 5/30/24: Merck to Acquire EyeBio, Financial Burden of Private Healthcare Increased Over the Past Two Decades & more

FDA Grants Priority Review to Keytruda Combination as a First-Line Treatment for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Priority review designation for Keytruda is based on promising results from the Phase II/III IND.227/KEYNOTE-483 trial, which demonstrated improved overall survival in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Financial Burden of Private Healthcare Increased Over the Past Two Decades

Private healthcare is becoming more expensive for the nearly 180 million American families covered, according to the results of a study published in a JAMA Internal Medicine research letter.

Smart Bandages That Heal Wounds Faster and Talk to Your Doctor Are on the Way

Researchers are working on bandages that allow remote monitoring and deliver treatment with zaps of light or electricity.

Merck to Acquire EyeBio

Merck, known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

Dana Benson on LinkedIn:

#RFID supports a more efficient and accurate medication-use process that can enhance #patientsafety, help prevent drug diversion, and give clinicians more time for patient care.https://ow.ly/Q5sY50RAizt Pharmaceutical Commerce MagazineFresenius Kabi #GS1Standards

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs